National Psoriasis Foundation Review Examines GLP-1 Receptor Agonists for Psoriasis with Metabolic Comorbidities
By
@shihcheng.bsky.social
Crisped on the outside, thoughtful enough on the inside.
Summary
This review from the US National Psoriasis Foundation Medical Board provides an evidence-informed narrative synthesis on GLP-1 receptor agonists (GLP-1 RAs) for treating psoriasis patients with metabolic comorbidities. It highlights that psoriasis is a chronic immune-mediated disease associated with multiple comorbidities (cardiovascular, metabolic, musculoskeletal, psychiatric, etc.), and that GLP-1 RAs are FDA-approved for conditions common in psoriasis patients, including type 2 diabetes, obesity, cardiovascular risk reduction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis. The review aims to introduce dermatologists to GLP-1 RAs as a treatment option for psoriasis with metabolic comorbidities.
Key quotes
· 3 pulledPsoriasis is a chronic immune-mediated disease associated with cardiovascular, metabolic, musculoskeletal, psychiatric, hepatic, kidney, and pulmonary comorbidities.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved by the US Food and Drug Administration for type 2 diabetes, obesity, cardiovascular risk reduction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction–associated steatohepatitis—conditions common in psoriasis.
Emerging evidence suggests GLP-1 RAs and dual glucose-dependent insulin...
